{"name":"Shanghai Shyndec Pharmaceutical Co., Ltd.","slug":"shanghai-shyndec-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Adalat","genericName":"Adalat","slug":"adalat","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"nifedipine CR tablets (Adalat)","genericName":"nifedipine CR tablets (Adalat)","slug":"nifedipine-cr-tablets-adalat","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"Adalat","genericName":"Adalat","slug":"adalat","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"nifedipine CR tablets (Adalat)","genericName":"nifedipine CR tablets (Adalat)","slug":"nifedipine-cr-tablets-adalat","phase":"marketed","mechanism":"Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.","indications":["Hypertension","Angina pectoris (chronic stable angina)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiSkFVX3lxTE9vc1FNaVR0cHpjTkowMWdRMU5qVEZwajk4VXlGYTV6a1ZuSUlhSlhiREtoU2lab285V2hJWmp5SDh0Xy1wbndmVHNB?oc=5","date":"2024-03-04","type":"pipeline","source":"澳門特別行政區政府入口網站","summary":"UM, Sinopharm establish cooperation in biomedical sciences – Macao SAR Government Portal - 澳門特別行政區政府入口網站","headline":"UM, Sinopharm establish cooperation in biomedical sciences – Macao SAR Government Portal - 澳門特別行政區政府入口網站","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1aOWRXYWZEMUhZeTQ2VWVFcU9Hc1QtZk1ReC1SckRNMG9ENHVGeldfeV9leHY2Z0tqUFIzeFA0UW9hLTlZNDdlVFlzV1VhY3dyY2Eza1NVVC1ObEFlTWU0UEx6c1JFN3VRd1NHOGRfUHdhaDg?oc=5","date":"2020-08-18","type":"pipeline","source":"marketscreener.com","summary":"MedRx Co., Ltd Stock (4586) - Quote Japan Exchange - marketscreener.com","headline":"MedRx Co., Ltd Stock (4586) - Quote Japan Exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNZGFnTFBMX1c1d0VBTDhHUk9vMEVSY21pczFwamhkZDVQYlBJN0F0LTFvUVpraHRQWDlpU21od1BEZXhKemp2T0xjdFFiV3NobGZsRnNPM1FpeXQtQ1hWS3dSTTQwRTJyQU96T1RxaGVyQ3QzZmt0blZmUTJaS3pzOEI1SldmMlg1UHZLaA?oc=5","date":"2020-08-18","type":"pipeline","source":"marketscreener.com","summary":"Knight Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA4990531069 - marketscreener.com","headline":"Knight Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA4990531069","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNOGRsU3Z1Y0tmbldCWWZFc21TWE84RnFCSFVzUmVZSGV3SHFTX2dlX25FSkZ3YlVXRk41Z19GUWd4bURLMWs0X0xwVG45YjZPNVhXSFR1azNfWTN2QnFTZk9GS0o1eUhGZlZOVHl1M1FzMmExbmFMN21QdHM0OUlsR3hfZlFway1WSFdMR0J3SW9OVHlOSVo5N0I0WlZvNU5I?oc=5","date":"2020-03-30","type":"pipeline","source":"Asia Financial","summary":"Sinopharm Holdings plans corporate bonds not exceeding 5 billion yuan - Asia Financial","headline":"Sinopharm Holdings plans corporate bonds not exceeding 5 billion yuan","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}